InicioGLTO • NASDAQ
add
Galecto Inc
Cierre anterior
5,14 $
Intervalo diario
4,99 $ - 5,31 $
Intervalo anual
4,40 $ - 23,50 $
Cap. bursátil
6,70 M USD
Volumen medio
19,06 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Ingresos | — | — |
Gastos operativos | 3,84 M | -34,42 % |
Ingresos netos | -3,88 M | 52,27 % |
Margen de beneficio neto | — | — |
Beneficios por acción | -3,39 | 32,03 % |
EBITDA | -3,83 M | 32,07 % |
Tipo impositivo efectivo | -0,18 % | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 19,68 M | -55,46 % |
Activos totales | 23,38 M | -53,29 % |
Responsabilidades totales | 2,44 M | -80,73 % |
Patrimonio total | 20,94 M | — |
Acciones en circulación | 1,32 M | — |
Precio-valor contable | 0,31 | — |
Rentabilidad económica | -37,89 % | — |
Retorno sobre capital | -43,02 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -3,88 M | 52,27 % |
Efectivo de operaciones | -3,65 M | 56,81 % |
Efectivo de inversión | 0,00 | -100,00 % |
Efectivo de financiación | — | — |
Variación neta del flujo de caja | -3,18 M | -2.709,84 % |
Flujo de caja libre | -2,08 M | 44,50 % |
Información sobre la empresa
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Director ejecutivo
Fundación
2011
Sitio web
Empleados
13
